<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101124171</journal-id>
<journal-id journal-id-type="pubmed-jr-id">29776</journal-id>
<journal-id journal-id-type="nlm-ta">Nat Rev Drug Discov</journal-id>
<journal-id journal-id-type="iso-abbrev">Nat Rev Drug Discov</journal-id>
<journal-title-group>
<journal-title>Nature reviews. Drug discovery</journal-title>
</journal-title-group>
<issn pub-type="ppub">1474-1776</issn>
<issn pub-type="epub">1474-1784</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29217837</article-id>
<article-id pub-id-type="pmc">6287751</article-id>
<article-id pub-id-type="doi">10.1038/nrd.2017.226</article-id>
<article-id pub-id-type="manuscript">NIHMS998546</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Drug development in the era of precision medicine</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Dugger</surname>
<given-names>Sarah A.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Platt</surname>
<given-names>Adam</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Goldstein</surname>
<given-names>David B.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Institute for Genomic Medicine, Columbia University Medical Center, Hammer Health Sciences, 1408, 701 West 168th Street, New York, New York 10032, USA.</aff>
<aff id="A2"><label>2</label>Department of Genetics &amp; Development, Columbia University Medical Center, Hammer Health Sciences, 1602, 701 West 168th Street, New York, New York 10032, USA.</aff>
<aff id="A3"><label>3</label>AstraZeneca Centre for Genomics Research, Precision Medicine and Genomics, IMED Biotech Unit, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK.</aff>
<author-notes>
<corresp id="CR1">Correspondence to D.B.G. <email>dg2875@cumc.columbia.edu</email></corresp>
<fn fn-type="COI-statement" id="FN2">
<p id="P57">Competing interests statement</p>
<p id="P58">The authors declare <underline>competing interests</underline>: see Web version for details.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>28</day>
<month>11</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>08</day>
<month>12</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<month>3</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>10</day>
<month>12</month>
<year>2018</year>
</pub-date>
<volume>17</volume>
<issue>3</issue>
<fpage>183</fpage>
<lpage>196</lpage>
<!--elocation-id from pubmed: 10.1038/nrd.2017.226-->
<abstract id="ABS1">
<p id="P2">For the past three decades, the use of genomics to inform drug discovery and development pipelines has generated both excitement and scepticism. Although earlier efforts successfully identified some new drug targets, the overall clinical efficacy of developed drugs has remained unimpressive, owing in large part to the heterogeneous causes of disease. Recent technological and analytical advances in genomics, however, have now made it possible to rapidly identify and interpret the genetic variation underlying a single patient’s disease, thereby providing a window into patient-specific mechanisms that cause or contribute to disease, which could ultimately enable the ‘precise’ targeting of these mechanisms. Here, we first examine and highlight the successes and limitations of the earlier phases of genomics in drug discovery and development. We then review the current major efforts in precision medicine and discuss the potential broader utility of mechanistically guided treatments going forward.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>